The head and neck district represents one of the most frequent sites of cancer, and the
percentage of metastases is very high in both loco-regional and distant areas. Prognosis …

The clinical and biological heterogeneity of head and neck cancer (HNC) is paralleled by a
plethora of different symptoms that affect the patient's quality of life. These symptoms …

Background Immune checkpoint inhibitors are widely used in recurrent and/or metastatic
head and neck squamous cell carcinoma (R/M HNSCC). We aimed to describe response …

Objective Recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)
treatment has changed dramatically with the introduction of immune checkpoint inhibitors …

De novo metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) constitutes 10% of
recurrent/metastatic (RM) cases. Radiotherapy (RT) has a crucial role in the treatment of …

Abstract Background/Objectives: Limited metastatic squamous cell carcinoma of the
oropharynx (OPC) lacks clear management guidelines, especially for HPV-associated …

Head and neck carcinomas are initially metastatic in about 15% of cases. Radiotherapy is a
cornerstone in the multimodal strategy at the locoregional phase. In patients with head and …

Despite recent advances in multimodality treatments such as endocrine therapy,
chemotherapy, molecularly targeted therapy, and radiation therapy, it is still very difficult to …

Purpose Patients with synchronous metastatic head and neck squamous cell carcinomas
often present associated locoregional symptoms and a risk of life-threatening primary …

Abstract Purpose A Benchmark Case (BC) was performed as part of the quality assurance
process of the randomized phase 2 GORTEC 2014-14 OMET study, testing the possibility of …